PlainPharmaWatch

CMS Open Payments · Program Year 2024

Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. reported $1,770,049.33 in payments to 344 physicians and teaching hospitals across 789 transactions.

See the rankings → How this is sourced
$1.8M
Total payments
789
Transactions
344
Recipients
−$510.3K
General Payments vs PY2023

Amylyx Pharmaceuticals, Inc. reported $1,770,049.33 in payments to 344 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #479 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $5.1K per recipient across 5 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Amylyx Pharmaceuticals, Inc. pairs top-quartile payment volume with a broadly spread payment pattern across many recipients.

#479
of 1,925 companies
0.0%
of all US industry payments
0.3%
paid to its single top recipient
5
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Amylyx Pharmaceuticals, Inc.'s CMS-reported General Payments decreased by $510.3K (−87.8%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2023: AMYLYX PHARMACEUTICALS, INC.PY2024: Amylyx Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$581.1KPY2024$70.8K
PY2023
$581,114.76
PY2024
$70,765.68

How Amylyx Pharmaceuticals, Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Amylyx Pharmaceuticals, Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$1,770,049 Top 25% higher than 75% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). This entry sits in this band. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Amylyx Pharmaceuticals, Inc.

$1,770,049.33: that is what Amylyx Pharmaceuticals, Inc. reported in payments to 344 physicians and teaching hospitals during Program Year 2024, spread across 789 transactions ($2.2K per transaction, $5.1K per recipient). The company sits at rank #479 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

"Consulting Fee" leads the 5-category general-payment breakdown below at $33.4K (1.9% of the company's reported total, 12 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Amylyx Pharmaceuticals, Inc. made 5 types of general payments. "Consulting Fee" is the largest category at $33.4K, 1.9% of the company's reported total.

How Amylyx Pharmaceuticals, Inc. divides its payments

Ranked by total dollars reported per category

1. Consulting Fee$33.4K2. Honoraria$16.4K3. Food and Beverage$10.6K4. Space Rental or Facility …$10.0K5. Travel and Lodging$295.47
Payment Type Amount Transactions
Consulting Fee $33.4K 12
Honoraria $16.4K 23
Food and Beverage $10.6K 303
Space Rental or Facility Fees $10.0K 3
Travel and Lodging $295.47 3

Recipient Concentration in General Payments

The five largest recipient relationships account for $40,721.56 (57.5%) of $70,765.68 in this company's General Payments records across 262 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Amylyx Pharmaceuticals, Inc.

The five named recipients with the highest reported General Payments from this company

Bernhardt Zeiher$21.5KSabrina Paganoni$7.3KMayo Clinic Hospital$4.5KLangley Porter Psychiatric H…$4.0KJeffrey Rosenfeld$3.4K
  1. 1

    Bernhardt Zeiher

    $21,518.91 across 5 reported transactions

  2. 2

    Sabrina Paganoni

    $7,350.00 across 2 reported transactions

  3. 3

    Mayo Clinic Hospital

    $4,500.00 across 1 reported transactions

  4. 4

    Langley Porter Psychiatric Hospital

    $4,000.00 across 1 reported transactions

  5. 5

    Jeffrey Rosenfeld

    $3,352.65 across 4 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $2.2K. Average per recipient: $5.1K.

Total Amount

$1,770,049.33

Avg per Transaction

$2.2K

Avg per Recipient

$5.1K

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Amylyx Pharmaceuticals, Inc. Share

0.0%

#479 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Amylyx Pharmaceuticals, Inc.

Preceptis Medical, Inc.

$1.8M 109 recipients

Aegis Spine, Inc.

$1.8M 38 recipients

GT Medical Technologies, Inc

$1.8M 808 recipients

Dendreon Pharmaceuticals LLC

$1.8M 10,334 recipients

Medivation LLC.

$1.7M 3 recipients

Merz Pharmaceuticals, LLC

$1.8M 7,100 recipients

Frequently Asked Questions

How much did Amylyx Pharmaceuticals, Inc. pay to physicians and hospitals in 2024? ▾
Amylyx Pharmaceuticals, Inc. made $1,770,049.33 in payments to physicians and hospitals in Program Year 2024, across 789 individual transactions. This represents 0.0% of all industry payments reported to CMS Open Payments.
How many physicians received payments from Amylyx Pharmaceuticals, Inc.? ▾
Amylyx Pharmaceuticals, Inc. made payments to 344 physicians and teaching hospitals in 2024. The average payment per recipient was $5.1K.
What types of payments did Amylyx Pharmaceuticals, Inc. make? ▾
General payments from Amylyx Pharmaceuticals, Inc. span 5 distinct categories, covering things like consulting, meals, and travel. The largest general-payment category was "Consulting Fee" at $33.4K, representing 1.9% of the company's reported total.
How does Amylyx Pharmaceuticals, Inc. rank among pharmaceutical companies? ▾
Amylyx Pharmaceuticals, Inc. ranks #479 out of 1,925 companies by total payment amount in the CMS Open Payments database for 2024.
What is the average payment size from Amylyx Pharmaceuticals, Inc.? ▾
The average transaction from Amylyx Pharmaceuticals, Inc. was $2.2K in 2024. The company made 789 total transactions to 344 recipients.
Where does the payment data for Amylyx Pharmaceuticals, Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Amylyx Pharmaceuticals, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.